Immatics N.V.: Guggenheim sees around 95% price potential after reviewing the quarterly report and study progress!
Reading Time: 4 minutes
Immatics N.V. positions itself as a leading biopharmaceutical company in the field of precision cancer immunotherapy, with the main focus on the PRAME antigen, which is highly expressed in over 50 cancer types. Immatics' solutions for cancer patients are based on two complementary modalities: autologous TCR-T cell therapy and bispecific TCR molecules (TCER), which are developed as "off-the-shelf" solutions. The TCR-T cell therapy (ACTengine) like the lead product Anzu-cel (IMA203) utilizes patient-derived T cells to target PRAME-expressing tumors....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
